Related by context. All words. (Click for frequent words.) 73 generalisability 67 residual confounding 65 limiting generalizability 65 methodologic 64 subgroup analyzes 64 prospective longitudinal 63 sociodemographic characteristics 63 Subgroup analyzes 63 VADT 63 nonrandomized 63 unmeasured factors 62 correlational 62 EGFR mutation status 62 Observational studies 62 predictive validity 62 causal inference 62 CLBP 61 HER2 expression 61 psychiatric comorbidity 61 unmeasured confounders 61 methodological limitations 61 generalisable 60 antioxidant supplementation 60 observational studies 60 generalizable 60 randomized controlled trials RCTs 60 biologic plausibility 60 RCTs 60 autonomic dysfunction 60 nonpharmacologic 60 adjuvant therapies 60 unmeasured confounding 60 psychiatric comorbidities 60 Clinical Antipsychotic Trials 60 DHEA supplementation 60 periprocedural MI 60 syndromal 59 genotypic resistance 59 STEP BD 59 attain statistical significance 59 comorbidity 59 lipid lowering therapy 59 plasma pharmacokinetics 59 ELBW infants 59 alexithymia 59 aldosterone antagonist 59 nonadherence 59 perioperative morbidity 59 retrospective cohort 58 ALLHAT 58 convergent validity 58 serum vitamin D 58 familial aggregation 58 MMSE score 58 beta carotene supplementation 58 multivariate analyzes 58 prostate carcinogenesis 58 hippocampal volume 58 Meta analyzes 58 elevated CRP 58 interobserver 58 Longitudinal studies 58 NICE SUGAR 58 meta analyzes 58 CPAP adherence 58 noncognitive 58 meta regression 58 intraobserver 58 comorbid depression 58 thyrotropin levels 58 liver transplant recipients 58 HIV HCV coinfected 58 meta analytic 58 Subgroup analysis 57 interindividual variability 57 PROactive study 57 chemoprevention trials 57 carotid IMT 57 F FDG PET 57 prognostic indicators 57 Heritability 57 neurocognitive functioning 57 randomized controlled trials 57 multivariable analysis 57 confounder 57 inflammatory biomarkers 57 Intervention Trial 57 Intervention Effectiveness CATIE 57 neurocognitive function 57 MDRD equation 57 elevated homocysteine 57 confounding variables 57 radiographic outcomes 57 Reynolds Risk Score 57 SGAs 57 Cognitive impairment 57 hypercoagulable 57 trials RCTs 57 vitamin D inadequacy 57 metaanalysis 57 differential gene expression 57 testosterone supplementation 57 oncologic outcomes 57 silent myocardial ischemia 57 cardioprotective effects 57 randomized trials 57 #q# deletion 57 methodological weaknesses 57 choline intake 57 sonographic diagnosis 57 subclinical hypothyroidism 57 vitamin B# supplements 57 comorbid conditions 57 multicenter trials 57 prognostic variables 57 noninferiority 57 EGFR expression 57 colorectal neoplasia 57 probiotic supplementation 57 Rigorous scientific 57 CYP#D# genotype 56 Vertos II 56 neurocognitive impairment 56 exploratory endpoints 56 stone formers 56 epidemiologic studies 56 psychiatric outpatients 56 ICD therapy 56 dose proportionality 56 pharmacokinetic interaction 56 nonrandomized studies 56 cerebral oxygenation 56 APOE genotype 56 randomized clinical 56 prospectively defined 56 IGRAs 56 etiological 56 neurodevelopmental outcomes 56 postoperative AF 56 Multicenter Automatic Defibrillator Implantation 56 coronary calcification 56 clinicopathological 56 cranial irradiation 56 retrospective cohort study 56 folate supplementation 56 multiple logistic regression 56 logistic regression analyzes 56 poor metabolizers 56 KRAS variant 56 sociodemographic factors 56 antenatal depression 56 placebo controlled trials 56 pharmacodynamic parameters 56 ACCORD Lipid 56 interrater reliability 56 plasma lipid 56 homocysteine concentrations 56 PLCO 56 vitamin D supplementation 56 perioperative complications 56 INTERHEART 56 prospectively stratified 56 prospective observational cohort 56 PREVENT IV 56 underdiagnosis 56 pharmacologic treatments 56 observational cohort 56 interobserver reliability 56 diagnosing ADHD 56 Sociodemographic 56 clinico pathological 56 Cochrane reviewers 56 cytologic 56 adrenal function 56 ASCEND HF 56 nonfasting triglyceride levels 56 serum lipid levels 56 T1DM 56 subsyndromal 56 noncardiac 56 comorbid disorders 56 depressive symptomatology 56 carotid plaque 56 prostate cancer CaP 56 Randomized trials 56 nondemented 56 IMPROVE HF 56 dietary calcium intake 56 ConclusionThis 56 postmenopausal hormones 56 HeFT 55 serum folate concentrations 55 longitudinal cohort study 55 Multivariate analyzes 55 prognostic significance 55 etiologic 55 neurodevelopmental outcome 55 ALI ARDS 55 MetS 55 RE LY trial 55 lymph node involvement 55 dietary intakes 55 folate intake 55 magnesium intake 55 psychotherapeutic interventions 55 glycemia 55 GH deficiency 55 PIX# [002] 55 familial clustering 55 SpHb monitoring 55 tumor histology 55 riociguat 55 meta analysis 55 transient elastography 55 albumin excretion 55 TT genotype 55 subanalysis 55 CYP#C# genotype 55 heterogeneity 55 intracranial stenosis 55 selenium supplementation 55 baseline HbA1c 55 plasma homocysteine 55 placebo controlled clinical 55 bivariate 55 retrospective observational 55 atherothrombotic disease 55 metabolic parameters 55 patients undergoing CABG 55 BARI 2D 55 p# biomarker 55 hsCRP levels 55 newer atypical antipsychotics 55 authors hypothesized 55 β blockers 55 Kaplan Meier curve 55 surrogate markers 55 cerebral microbleeds 55 longitudinal studies 55 HCV SPRINT 55 blinded randomized controlled 55 atherogenic dyslipidemia 55 somatoform disorders 55 statistically significant correlations 55 mechanistic explanation 55 carotid bruit 55 serum uric acid 55 bivariate analyzes 55 SCK difficulty 55 STRIDE PD 55 pretest probability 55 macrovascular disease 55 Prostate Cancer Prevention 55 #F FDG PET 55 paclitaxel eluting stents 55 immunohistochemical 55 KRAS mutation 55 heritable variation 55 randomizing patients 55 NIHSS score 55 hydroxyvitamin D concentrations 55 Prostate Lung Colorectal 55 phytoestrogen intake 55 CAVEATS 55 multivariate Cox 55 MMSE scores 55 kidney allograft 55 abnormal glucose tolerance 55 Leitzmann 55 multivariable analyzes 55 viral kinetics 55 lipid lowering medications 55 Winkelmayer 55 conventional angiography 55 premorbid 55 Non inferiority 55 coinfected patients 55 randomized controlled trial 55 causal inferences 55 chronic LBP 55 histological subtype 55 Systematic reviews 55 SYNTAX trial 55 Dr. Chenchen Wang 55 BRCA testing 55 bivariate analysis 55 corneal thickness 55 thromboprophylaxis 55 FDG PET 55 HRQOL 55 CVD mortality 55 carotid angioplasty 55 abdominal adiposity 55 antitumor effect 55 dietary interventions 54 circulating endothelial cells 54 nonvertebral fracture 54 LV dysfunction 54 echocardiographic parameters 54 psychometric properties 54 calcium supplementation 54 coronary CTA 54 shorter telomere length 54 postoperative morbidity 54 CARDIA 54 gallstone disease 54 APOE e4 54 SORT OUT III 54 prospective multicentre 54 antiretroviral naïve 54 Multiple logistic regression 54 carotid atherosclerosis 54 warfarin dosing 54 morphometric vertebral fractures 54 multivariable adjusted 54 myocardial ischaemia 54 brachial blood 54 dose Iluvien 54 metabolic syndrome MetS 54 AMOR IPAT 54 carotid stenosis 54 multicentre prospective 54 efficacy evaluable 54 genomewide 54 antihypertensive therapy 54 psychosocial functioning 54 ICD implantations 54 body habitus 54 conditional logistic regression 54 Digital Mammographic Imaging 54 atherosclerotic renal artery stenosis 54 BMD measurements 54 serum urate levels 54 microsatellite instability 54 EUS FNA 54 atypical antipsychotic medications 54 sociodemographic 54 mammographic density 54 postintervention 54 hepatic fibrosis 54 logistic regression models 54 comorbidities 54 non pharmacological interventions 54 pharmacodynamic endpoints 54 baseline LDH 54 hematopoietic cancers 54 Singh Manoux 54 pharmacokinetic interactions 54 ExTRACT TIMI 54 chest radiographs 54 ascertainment bias 54 virologic responses 54 CORE OM 54 perinatal outcomes 54 logistic regression analysis 54 neuropsychiatric symptoms 54 nulliparous women 54 narcolepsy cataplexy 54 placebo controlled studies 54 dose statin therapy 54 K ras mutations 54 confirmatory clinical 54 HYVET 54 orofacial clefts 54 psychiatric morbidity 54 Baseline characteristics 54 Epidemiologic studies 54 Multivariate logistic regression 54 nondiabetic patients 54 RE LY 54 spirometric 54 prospective cohort 54 CHADS2 54 telomere lengths 54 thiazide diuretics 54 monoclonal gammopathy 54 KRAS status 54 mutated K ras 54 vitamin D insufficiency 54 cellularity 54 fragility fracture 54 pCR 54 subclinical atherosclerosis 54 prophylactic cranial irradiation 54 pleiotropic effects 54 advanced neoplasia 54 multicenter study 54 univariate analyzes 54 EMPOWER TM 54 NNRTI resistance 54 glomerular filtration 54 ICD implantation 54 cardiac autonomic 54 postoperative mortality 54 optimal dosing 54 intensive statin therapy 54 observational study 54 Secondary efficacy endpoints 54 Colorectal cancer screening 54 psychobiological 54 BRFSS 53 biopsychosocial 53 mechanistic insights 53 platelet activation 53 ONTARGET 53 Calcium intake 53 Univariate analysis 53 underlying pathophysiology 53 Primary endpoints 53 mixed hyperlipidemia 53 tibolone 53 clinicopathologic 53 endoscopists 53 preintervention 53 androgen deficiency 53 RE LY ® 53 methodological flaws 53 elevated triglycerides 53 nondepressed 53 chromium picolinate supplementation 53 untreated OSA 53 biologic DMARDs 53 androgen suppression 53 epidemiologic 53 K ras mutation 53 suicide attempters 53 aldosterone antagonists 53 methodologically rigorous 53 gastric carcinoma 53 HAART regimens 53 serum creatinine levels 53 OSAHS 53 randomized controlled clinical trials 53 prospective multicenter study 53 antiepileptics 53 MELD scores 53 preoperative diagnosis 53 nonselective NSAIDs 53 Wisconsin Sleep Cohort 53 body fatness 53 achieved statistical significance 53 adjuvant radiation 53 estimated GFR 53 genotypic 53 electrophysiologic 53 CALGB 53 HORIZONS AMI trial 53 ImmuKnow assay 53 oncological outcomes 53 Randomized clinical trials 53 empiric 53 allele frequencies 53 creatine supplementation 53 serum calcium 53 virologic 53 virological response 53 iron supplementation 53 HF ACTION 53 thrombophilia 53 Framingham Offspring Study 53 chromium supplementation 53 lymphadenectomy 53 intact parathyroid hormone 53 nonfasting triglycerides 53 venous thromboembolic disease 53 pyridostigmine 53 subthreshold depression 53 NHANES III 53 socioeconomic status SES 53 somatic symptoms 53 serum BDNF 53 antipsychotic prescribing 53 Symptom severity 53 KIF6 carriers 53 plain radiographs 53 colorectal liver metastases 53 cardioprotective effect 53 noncancer 53 colorectal adenoma 53 stepwise logistic regression 53 hydroxyvitamin D levels 53 gonococcal infections 53 tertiles 53 SNP rs# [002] 53 tele ICU 53 neurosensory 53 pharmacological therapies 53 postoperative radiotherapy 53 dietary modification 53 myocardial viability 53 antidepressant efficacy 53 INVEGA ® 53 dietary folate intake 53 CHD mortality 53 antibody titer 53 vascular dysfunction 53 histopathological 53 PNH patients 53 HER2 overexpression 53 dysglycemia 53 functional neuroimaging 53 randomized clinical trials 53 undergoing CABG 53 substudy 53 pathophysiological mechanisms 53 familial predisposition 53 transferrin saturation 53 venlafaxine XR 53 generalized estimating 53 paroxysmal AF 53 IUGR 53 lowering homocysteine 53 pentoxifylline 53 nodal metastases 53 sociodemographic variables 53 impaired cognition 53 poststroke 53 genetic polymorphisms 53 pharmacologic intervention 53 serum biomarkers 53 antibiotic prophylaxis 53 mean ± SEM 53 guideline concordant 53 #q# deletion syndrome 53 FDG PET imaging 53 neuroimaging studies 53 potentially modifiable 53 inferential statistics 53 adiponectin levels 53 meta analytic review 53 prospectively enrolled 53 authors conclude 53 Intervention Effectiveness 53 semistructured interviews 53 Genetic predisposition 53 prognostic markers 53 adiponectin concentrations 53 Tumor Response 53 KRAS mutations 53 chemosensitivity 53 nonischemic 53 Multivariate analysis 53 plasma folate 53 maximally tolerated dose 53 pharmacological approaches 53 retrospective observational study 53 hormone receptor status 53 stratifying patients 53 prognostically 53 BRCA mutation carriers 53 AVERROES 53 serum selenium 53 NATRECOR R 53 routine episiotomy 53 BRCA mutations 53 fructose intake 53 white matter hyperintensities 53 psychiatric diagnoses 53 carotid artery stenting CAS 53 prespecified 53 folate intakes 53 Roxana Mehran MD 53 BRCA2 carriers 53 SLNB 53 dyslipidaemia 53 immunological responses 53 venous thromboembolism prophylaxis 53 oral anticoagulation 53 pharmacogenetic testing 53 pleiotropy 53 obstructive coronary artery 53 Logistic regression 53 nutrient supplementation 53 NAMCS 52 leukocyte count 52 multiple linear regression 52 Cardiorespiratory fitness 52 symptomatic VTE 52 ragweed allergic 52 somatization disorder 52 virological failure 52 sociodemographics 52 analgesic efficacy 52 decompensated cirrhosis 52 Vauthey 52 Cardiovascular Risk 52 Coronary CTA 52 lymph node dissection 52 Bonferroni correction 52 chlamydial infection 52 proton MR spectroscopy 52 MADIT II 52 spontaneous preterm delivery 52 REACH Registry 52 chronic prostatitis chronic 52 UKPDS 52 methodological shortcomings 52 CSF biomarkers 52 observational cohort study 52 HbA1c levels 52 nomograms 52 abnormal cytology 52 abnormal lipid levels 52 unconscious biases 52 fasting triglyceride levels 52 antiarrhythmic drug 52 ginkgo extract 52 biological plausibility 52 fragility fractures 52 mechanistic studies 52 endocrinologic 52 androgen depletion 52 topical NSAIDs 52 multicentric 52 acetabular dysplasia 52 Dr. Fehlings 52 interobserver agreement 52 perimenopausal women 52 serum ferritin 52 platelet reactivity 52 carotid plaques 52 MYH9 52 pegylated interferon alfa 2b 52 methodological differences 52 neurophysiologic 52 Heavy menstrual bleeding 52 HRQL 52 methodological rigor 52 extracolonic findings 52 sotalol 52 prospective observational studies 52 fructose intolerant 52 juvenile idiopathic arthritis 52 Statin therapy 52 microdeletions 52 Bioavailability 52 coexisting illnesses 52 GnRH agonists 52 MDRD 52 cilostazol 52 hyperactivity inattention 52 Haptoglobin 52 IPAH 52 renal artery stenosis 52 perioperative mortality 52 univariate 52 serum PSA 52 Jackevicius 52 pharmacologic interventions 52 salivary cortisol 52 GBA mutations 52 HNSCC 52 ABCB1 52 radiographic findings 52 AChE inhibitors 52 genomic biomarker 52 BPS IC 52 neurocognitive deficits 52 troponin T 52 hippocampal volumes 52 posttest 52 advanced adenoma 52 reach statistical significance 52 pulmonary nodules 52 clinical pharmacology studies 52 CARE HF 52 systolic dysfunction 52 nonrepresentative 52 Ascherio 52 ImmuKnow 52 thyrotropin 52 secondary efficacy endpoint 52 diagnosing bipolar disorder 52 ischemic lesions 52 Echocardiographic 52 postoperative chemotherapy 52 coinfection 52 renal toxicity 52 lymph node metastasis 52 prostate carcinoma 52 perfusion abnormalities 52 postexposure prophylaxis 52 Ovarian Cancer Screening 52 STICH trial 52 osteoporotic vertebral compression fractures 52 subclinical cardiovascular disease 52 penetrance 52 noncardiac chest pain 52 cecal intubation 52 serum homocysteine 52 statistical significance 52 warfarin therapy 52 Zevalin consolidation 52 posttreatment 52 Dose escalation 52 BCR ABL mutations 52 cardioembolic stroke 52 Multicenter AIDS 52 QTc intervals 52 clinically meaningful differences 52 acetabular fractures 52 intracerebral haemorrhage 52 randomized controlled clinical 52 arthrography 52 CD# upregulation 52 mammographic breast density 52 multivariate logistic regression 52 neuropsychological impairment 52 dosimetric 52 blood Phe levels 52 subtrochanteric 52 prospective nonrandomized 52 statistically nonsignificant 52 Chronic Heart Failure 52 concomitant medications 52 HSCT 52 neutrophil counts 52 immunohistochemical staining 52 APTIVUS r 52 isolated systolic hypertension 52 psychotherapies 52 Carotid Revascularization Endarterectomy vs. 52 APOE ε4 52 plasma selenium 52 fasting glucose levels 52 clinicopathological features 52 EQ 5D 52 EBV infection 52 virologic failure 52 APTIMA HPV 52 CYP#D# inhibitor 52 Univariate 52 coronary stenosis 52 psychoeducation 52 chronicity 52 scintigraphic 52 postoperative complications 52 contraindicate 52 arteriography 52 CC genotype 52 renoprotective 52 nonpregnant women 52 HbA1C 52 clinically evaluable 52 cardiometabolic risk 52 vitamin supplementation 52 CAM modalities 52 catheter angiography 52 intelligence quotient IQ 52 English proficiency LEP 52 Poisson regression 52 differentially expressed genes 52 Bioequivalence 52 serum IgE 52 Histologic 52 Cardiotoxicity 52 HbA1C levels 52 liver biopsies 52 premenopausal 52 airway responsiveness 52 postmenopausal hormone therapy 52 INTERHEART study 52 statin therapy 52 postmenopausal estrogen 52 titrated glipizide 52 prognostic factors 52 psychopathological symptoms 52 amnestic MCI 52 coronary revascularization 52 urate levels 52 left ventricular diastolic 52 multicentre study 52 cognitive behavioral therapies 52 cardiovascular mortality 52 osteopenic 52 anthropometric measurements 52 cardiac perfusion 52 nonfasting 52 Lipid Lowering Treatment 52 medically inoperable 52 Shlipak 52 Heterogeneity 52 gene loci 52 neuropathological 52 neurologic complications 52 EchoCRT 52 Outpatient Setting 52 paricalcitol 52 BRCA carriers 52 advanced adenomas 52 isoflavone supplement 52 morbidity mortality 51 longitudinal cohort 51 DAPT 51 nonpsychiatric 51 folic acid supplementation 51 neuromotor 51 ECOG PS 51 CLA supplementation 51 Depressive symptoms 51 Comorbidities 51 dopaminergic therapy 51 microbiologic 51 developmental trajectories 51 genotype phenotype 51 LTBI 51 medication nonadherence 51 intracranial hemorrhage ICH 51 bronchopulmonary dysplasia BPD 51 lung cancer chemoprevention 51 number NCT# ClinicalTrials.gov 51 extensive metabolizers 51 varicoceles 51 HIV tropism 51 lipid lowering drugs 51 serum estradiol 51 NHAMCS 51 recurrent UTI 51 Framingham Offspring 51 ION Stent 51 BEXXAR Therapeutic Regimen 51 pharmacodynamic effects 51 heterozygotes 51 nonoperative treatment 51 tumor subtype 51 euthymic patients 51 histologic subtype 51 everolimus eluting stents 51 cognitively intact 51 phase IIIb 51 elevated LDL cholesterol 51 carotid artery stenting 51 psychodynamic psychotherapy 51 serum GGT 51 MERLIN TIMI 51 Val HeFT 51 congenital toxoplasmosis 51 postprocedure 51 SPARCL 51 systolic hypertension 51 antihypertensive medications 51 dose escalation phase 51 EGFR mutations 51 cerebral infarction 51 dosage regimens 51 preoperative MRI 51 RTOG 51 NYHA functional class 51 thromboembolic 51 colorectal neoplasms 51 chronic myocardial ischemia 51 serum markers 51 cortical thickness 51 dietary folate 51 CALGB # [001] 51 DAS# scores 51 serum phosphorous 51 GRNCM1 51 ROCKET AF 51 SGRQ 51 EEG abnormalities 51 prescribe statins 51 lobular involution 51 causal pathways 51 Suicidal ideation 51 adenoma recurrence 51 poststroke depression 51 interobserver variability 51 procalcitonin 51 CD# expression [002] 51 Socio demographic 51 demyelinating 51 placebo controlled clinical trials 51 cirrhotic patients 51 CYPHER Stent 51 T2DM 51 pharmacokinetic parameters 51 nonpsychotic 51 nonalcoholic steatohepatitis 51 visceral metastases 51 nephron sparing surgery 51 antiplatelet therapy 51 calcaneal fractures 51 Acute Coronary Syndromes 51 VTE prophylaxis 51 double blinded randomized 51 radical cystectomy 51 specific antigen PSA 51 prospective randomized controlled 51 B vitamin supplementation 51 hypercholesterolemic patients 51 physiologic mechanisms 51 neuropsychological functioning 51 undergoing coronary angiography 51 comorbid psychiatric disorders 51 genetic locus 51 lipoprotein levels 51 subclinical hyperthyroidism 51 obese adolescents 51 empiric therapy 51 multicenter randomized controlled 51 seminomas 51 reperfusion therapy 51 antitumor efficacy 51 null hypothesis 51 urolithiasis 51 multivariate adjustment 51 XZK 51 periprocedural 51 dietary intake 51 morphologic 51 coadministration 51 ACCORD Eye 51 Descriptive statistics 51 seropositivity 51 ginkgo biloba extract 51 impair fertility 51 A1c levels 51 recurrent miscarriage 51 Logistic regression analysis 51 Arch Surg 51 statin medications 51 PITX2 methylation 51 intima media thickness 51 neuropsychological impairments 51 metastatic RCC 51 lipid lowering agents 51 retest reliability 51 preoperative chemotherapy 51 pharmacokinetic PK 51 relapsed MM 51 hawthorn extract 51 CR nPR 51 comorbid illnesses 51 d dimer 51 affective disorders 51 antihypertensive medication 51 eprotirome 51 virologic response 51 functional gastrointestinal disorders 51 HbA 1c levels 51 potential confounding variables 51 randomized crossover 51 impaired insulin secretion 51 PRIMO CABG2 51 liver metastasis 51 serologic testing 51 mild gestational diabetes 51 gp# vaccine 51 sonographic findings 51 HoLEP 51 acrylamide intake 51 pathophysiologic 51 covariate 51 subclinical disease 51 FDA defined valvulopathy 51 mitochondrial toxicity 51 folate deficiency 51 lymphocyte counts 51 myocardial ischemia 51 ADAGIO study 51 Vitamin D deficient 51 NSQIP 51 macronutrient intake 51 AIM HIGH 51 Dialysis Outcomes 51 thiopurine 51 elevated LDH 51 ACUITY trial 51 Cytogenetic 51 PITX2 51 randomized multicenter trial 51 flavopiridol 51 pancreatic adenocarcinoma 51 serotonin deficiency 51 rEEG 51 etiologic factors 51 antihypertensive drugs 51 nondiabetic 51 intensive lipid lowering 51 NMES 51 recurrent glioma 51 NAFLD 51 gonococcal 51 hemodialysis patients 51 antiretroviral naive 51 placebo controlled dose escalation 51 NATRECOR ® 51 HbA 1C 51 causal pathway 51 urine cytology 51 elevated creatinine 51 male Wistar rats 51 beta1 integrin 51 sensitivity specificity 51 incomplete revascularization 51 Pharmacogenetic 51 psychosocial stressors 51 hemoglobin A1c levels